Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
About the study
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed.
- Active choroidal neovascularization (CNV) lesions secondary to AMD that affect the central subfield in the study eye
- Total area of CNV>50% of the total lesion area in the study eye at screening
EXCLUSION CRITERIA
Exclusion Criteria:
- Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at Baseline.
- Central subfield of the study eye affected by fibrosis or geographic atrophy
- Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) >25 mmHg
- Previous treatment with any anti-VEGF drugs in the study eye.
- Previous treatment with any approved or investigational drugs for neovascular AMD in the study eye.
Other protocol-specified inclusion or exclusion criteria may apply.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Neovascular Age-Related Macular Degeneration
Age (in years)
50+
Phase
Phase 3
Participants needed
494
Est. Completion Date
Mar 5, 2024
Treatment type
Interventional
Sponsor
Novartis
ClinicalTrials.gov identifier
NCT04047472
Study number
CRTH258A2307
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?